Susquehanna International Group, LLP Xencor Inc Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Nov 16, 2020	SELL	$30.09 - $43.02 $481,440 - $688,320	-16,000 Reduced 74.07%	5,600 $217,000
Q1 2020 May 15, 2020	BUY	$20.69 - $37.79 $198,624 - $362,784	9,600 Added 80.0%	21,600 $645,000
Q4 2019 Feb 14, 2020	SELL	$32.75 - $41.43 $291,475 - $368,727	-8,900 Reduced 42.58%	12,000 $413,000
Q3 2019 Nov 14, 2019	BUY	$33.73 - $46.27 $704,956 - $967,043	20,900 New	20,900 $705,000
Q1 2019 May 15, 2019	SELL	$27.85 - $38.09 $233,940 - $319,956	-8,400 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$32.39 - $42.05 $80,975 - $105,125	2,500 Added 42.37%	8,400 $304,000
Q3 2018 Nov 14, 2018	SELL	$35.69 - $47.65 $92,794 - $123,890	-2,600 Reduced 30.59%	5,900 $230,000
Q2 2018 Aug 14, 2018	BUY	$28.41 - $42.41 $241,485 - $360,485	8,500 New	8,500 $315,000

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.44B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.